Want to see IL:NURI full AI Analyst Report?
Top Page
Nur
(TASE:NURI)
Select Model
Select Model
Rating:44Neutral
Price Target:
608.00
▼(-25.70% Downside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by weak financial performance—large ongoing losses and significant cash burn outweigh the healthier leverage position. Technicals are also a headwind given the strong downtrend, with only an oversold RSI offering limited near-term support. Valuation signals are constrained because the company is loss-making and offers no dividend yield.
Positive Factors
Revenue rebound
The rebound in revenue shows that the platform is generating greater activity than in the prior year, even from a small base. If this improvement persists, expanding transaction and service usage could provide a foundation for operating leverage and a broader commercial footprint over the next several quarters.
Negative Factors
Deep operating losses
The scale of losses relative to revenue indicates that Nur has not yet demonstrated a sustainable economic model. Negative gross profit means the core offering is not currently covering direct costs, while the large net loss limits internal funding and makes a credible path to profitability essential.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The rebound in revenue shows that the platform is generating greater activity than in the prior year, even from a small base. If this improvement persists, expanding transaction and service usage could provide a foundation for operating leverage and a broader commercial footprint over the next several quarters.
Read all positive factors
Nur (NURI) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪55.67M
Dividend YieldN/A
Average Volume (3M)8.97K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth104.30%
EPS Growth2.80%
CountryIL
Employees18
SectorGeneral
Sector StrengthN/A
IndustryIndustrial - Specialties
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,763,420
10 Day Avg. Volume3,702
30 Day Avg. Volume8,969
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.13
Price to Sales (P/S)265.22
P/FCF Ratio-11.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nur Business Overview & Revenue Model
Company Description
Nur Ink Innovations Ltd engages in the design, development, and production of water-based pigmented inks for digital inkjet printing applications in Israel. It offers Digital Sol-Gel, a water-based pigment ink for digital printing for direct-to-ga...
Nur Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
54
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 380.00K | 327.00K | 253.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.33M | -3.06M | -2.69M | -1.72M | -84.00 | -137.00 |
| EBITDA | -8.37M | -6.99M | -7.56M | -11.35K | -10.18M | -7.07M |
| Net Income | -11.24M | -9.42M | -9.66M | -12.86M | -11.61M | -7.78M |
Balance Sheet | ||||||
| Total Assets | 20.65M | 22.74M | 18.39M | 21.83K | 33.29K | 41.07K |
| Cash, Cash Equivalents and Short-Term Investments | 699.00K | 4.14M | 5.63M | 10.44K | 21.33K | 32.90K |
| Total Debt | 1.89M | 2.17M | 2.70M | 2.70K | 3.12K | 3.51K |
| Total Liabilities | 6.05M | 5.84M | 5.56M | 5.76K | 5.48K | 5.28K |
| Stockholders Equity | 14.60M | 16.90M | 12.83M | 16.08K | 27.80K | 35.80K |
Cash Flow | ||||||
| Free Cash Flow | -8.99M | -7.85M | -7.13M | -10.17K | -8.09K | -9.12K |
| Operating Cash Flow | -8.56M | -7.50M | -6.61M | -9.32K | -6.27K | -6.34K |
| Investing Cash Flow | -4.86M | -155.00K | 418.00K | 485.00 | -14.40K | -3.31K |
| Financing Cash Flow | 13.12M | 10.04M | 5.22M | -447.00 | -385.00 | 42.39K |
Nur Technical Analysis
Negative
818.30
Price Trends
727.85
Negative
803.01
Negative
970.47
Negative
Market Momentum
-27.92
Negative
29.25
Positive
93.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NURI, the sentiment is Negative. The current price of 818.3 is above the 20-day moving average (MA) of 659.65, above the 50-day MA of 727.85, and below the 200-day MA of 970.47, indicating a bearish trend. The MACD of -27.92 indicates Negative momentum. The RSI at 29.25 is Positive, neither overbought nor oversold. The STOCH value of 93.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NURI.
Nur Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₪17.07B | 33.61 | ― | 0.91% | 62.12% | 46.67% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₪55.67M | -4.38 | ― | ― | 104.30% | 2.80% | |
42 Neutral | ₪36.17M | -2.25 | ― | ― | -38.60% | -428.31% | |
41 Neutral | ₪40.47M | -4.09 | ― | ― | 12.14% | 43.83% | |
40 Underperform | ₪35.00M | -0.58 | ― | ― | -40.18% | 67.38% |
* General Sector Average
IL:NURI
Nur
633.00
-462.00
-42.19%
IL:VISN
Vision Sigma
3,843.00
-1,951.00
-33.67%
IL:SCDX
Scodix
108.90
-141.52
-56.51%
IL:PHTM
Photomyne
1,503.00
-741.00
-33.02%
IL:MSVT
Massivit
52.20
-26.70
-33.84%
IL:NXSN
Next Vision
18,460.00
3,850.00
26.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.